Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oncology nursing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Oncology nursing. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-002707-33 Sponsor Protocol Number: GS-US-352-0101 Start Date*: 2014-05-27
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thromboc...
    Medical condition: Primary Myleofibrosis (PMF) or post-Polycythemia vera or post-Essential Thrombocythemia Myelofibrosis (post-PV/ET MF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BE (Completed) GB (Completed) AT (Completed) SE (Completed) ES (Completed) HU (Completed) NL (Completed) DK (Completed) BG (Completed) RO (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004753-87 Sponsor Protocol Number: BBI608-901 Start Date*: 2020-03-18
    Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc.
    Full Title: A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Sumitomo Dainippon Pharma Oncology, Inc. sponsored Napabucasin Protocols
    Medical condition: Metastatic Pancreatic Adenocarcinoma and Metastatic Colorectal Cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006766-41 Sponsor Protocol Number: CP4055-202 Start Date*: 2007-03-13
    Sponsor Name:Clavis Pharma ASA
    Full Title: A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer
    Medical condition: A phase II clinical study of ELACYT as second line therapy in patients with advanced colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000879-14 Sponsor Protocol Number: CT/11.01 Start Date*: 2011-06-06
    Sponsor Name:Hellenic Oncology Research Group (H.O.R.G.)
    Full Title: A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC).
    Medical condition: Relapsed and Refractory Small Cell Lung Cancer
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022416-40 Sponsor Protocol Number: 3591 Start Date*: 2011-09-30
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A Translational, proof of the concept, study Of Pre-operative Pazopanib in treatment-naive patients with resectable soft tissue Sarcomas (TOPPS)
    Medical condition: Resectable Soft Tisue Sarcomas (cancer of conective soft tissues)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004851-19 Sponsor Protocol Number: AAPSMCS1002 Start Date*: 2014-07-29
    Sponsor Name:ACORN Research, LLC
    Full Title: A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma.
    Medical condition: Surgically unresectable or metastatic chondrosarcoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002365-63 Sponsor Protocol Number: GS-US-350-1937 Start Date*: 2017-04-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1b Study Followed by an Open label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS-5829 in Combination with Exemestane or Fulvestrant Comparing wi...
    Medical condition: Advanced Estrogen Receptor Positive HER2-Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005007-13 Sponsor Protocol Number: GS-US-352-1214 Start Date*: 2014-10-21
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibr...
    Medical condition: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001377-14 Sponsor Protocol Number: PimTo-MF-2014 Start Date*: 2014-06-30
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre
    Full Title: A multicenter, single arm, phase II clinical trial of pimecrolimus administered topically to patients with Stages Ia-IIa mycosis fungoides.
    Medical condition: Patients with Stages Ia-IIa of Mycosis Fungoides.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022770-13 Sponsor Protocol Number: ICORG10-01 Start Date*: 2011-01-12
    Sponsor Name:Cancer Trials Ireland
    Full Title: A phase II study of pazopanib in patients with metastatic or unresectable renal cell carcinoma (RCC) who have failed prior sunitinib therapy
    Medical condition: Metastatic or unresectable renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004552-64 Sponsor Protocol Number: 131016 Start Date*: 2017-07-03
    Sponsor Name:Center for Digestive Diseases, Karolinska University Hospital
    Full Title: MISTRAL - Mistletoe therapy in primary and recurrent inoperable pancreatic cancer - A phase III prospective, randomized, double blinded, multicenter, parallel group, placebo controlled clinical tr...
    Medical condition: Primary or recurrent inoperable pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004480-20 Sponsor Protocol Number: GS-US-370-1296 Start Date*: 2015-05-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by ...
    Medical condition: Untreated Metastatic Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073364 Ductal adenocarcinoma of pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) GB (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002766-39 Sponsor Protocol Number: ET13-002 Start Date*: 2021-02-17
    Sponsor Name:Centre Leon Berard
    Full Title: SIOP Ependymoma II - An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma
    Medical condition: Newly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellular, papillary, myxopapillary, clear-cell and tanycytic) or anaplastic ependymoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014967 Ependymoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) IE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004605-27 Sponsor Protocol Number: GS-US-494-5484 Start Date*: 2020-10-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002702-21 Sponsor Protocol Number: UKH062014 Start Date*: 2015-07-14
    Sponsor Name:Martin-Luther-Universität Halle- Wittenberg
    Full Title: A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients
    Medical condition: consolidation therapy in acute myeloid leukemia in first complete remission
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2016-003074-40 Sponsor Protocol Number: 201973 Start Date*: 2017-04-26
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ho...
    Medical condition: ER-positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001402-41 Sponsor Protocol Number: GS-US-296-2013 Start Date*: 2017-01-31
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroeso...
    Medical condition: unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) GB (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002618-40 Sponsor Protocol Number: HIT-REZ-2005 Start Date*: 2005-12-13
    Sponsor Name:Rheinische Friedrich-Wilhelms-University of Bonn, University Hospital
    Full Title: HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymoma...
    Medical condition: P-HIT-REZ 2005 study: Refractory and relapsed primitive neuroectodermal brain tumours (medulloblastomas, supratentorial PNETs) E-HIT-REZ 2005 study (Phase II Study "Oral therapy with temozolomide...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029211 Nervous system neoplasms malignant and unspecified NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004287-26 Sponsor Protocol Number: 5F9009 Start Date*: 2021-05-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplas...
    Medical condition: Intermediate/high/very high risk myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) BE (Completed) IE (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) NO (Prematurely Ended) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004040-10 Sponsor Protocol Number: GEIS-52 Start Date*: 2017-02-24
    Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS)
    Full Title: Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas
    Medical condition: Soft tissue sarcoma (undifferentiated pleomorphic sarcoma, synovial sarcoma, alveolar soft part sarcoma, clear cell sarcoma, angiosarcoma, epithelioid hemangiosarcoma, solitary fibrous tumor and ep...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 06 10:56:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA